Literature DB >> 12678333

Defining relapse of ulcerative colitis using a symptom-based activity index.

S L Jowett1, C J Seal, E Phillips, W Gregory, J R Barton, M R Welfare.   

Abstract

BACKGROUND: Several tools exist to assess disease activity in patients with ulcerative colitis (UC), but a definition of relapse does not exist. The aim of the study was to determine the score in the Simple Clinical Colitis Activity Index (SCCAI) that defined relapse. The reliability and validity of the SCCAI when self-administered was also examined.
METHODS: Patients with UC routinely attending hospital completed the SCCAI questionnaire, which was later administered by their clinician blinded to the scoring process. In the absence of a gold standard definition of relapse, a subjective global assessment of disease status was made by the clinician. The SCCAI was evaluated in a separate cohort of patients.
RESULTS: Seventy-one presentations were analysed; mean age 48 years, 49% male, 37% relapse rate. The mean patient score was 4.2 (range 0-14) and mean physician score 3.8 (0-14). A score of 5 or more defined relapse with 92% sensitivity, 93% specificity, 88% positive predictive value and 95% negative predictive value. The difference between the scores obtained by the patient and clinician (0.35, 95% CI 0.09-0.62) was small. Correlation with a more complex symptom and laboratory-based activity index was very high (r = 0.79, P < 0.01). The index was quick to use and comparative results for sensitivity and specificity were recorded in the second cohort of patients.
CONCLUSIONS: The SCCAI is a simple tool that can be accurately and quickly self-administered, correlates well with a more complex disease activity index, and can be used to define relapse of UC with high specificity and sensitivity.

Entities:  

Mesh:

Year:  2003        PMID: 12678333     DOI: 10.1080/00365520310000654

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  40 in total

1.  Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study.

Authors:  S L Jowett; C J Seal; M S Pearce; E Phillips; W Gregory; J R Barton; M R Welfare
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

2.  Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease.

Authors:  Millie D Long; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Robert S Sandler
Journal:  J Clin Gastroenterol       Date:  2016-02       Impact factor: 3.062

3.  Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis.

Authors:  Eun Soo Kim; Kyeong Ok Kim; Byung Ik Jang; Eun Young Kim; Yoo Jin Lee; Hyun Seok Lee; Seong Woo Jeon; Hyun Jin Kim; Sung Kook Kim
Journal:  Dig Dis Sci       Date:  2017-06-21       Impact factor: 3.199

4.  Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort.

Authors:  Lea K Christiansen; Bobby Lo; Flemming Bendtsen; Ida Vind; Marianne K Vester-Andersen; Johan Burisch
Journal:  United European Gastroenterol J       Date:  2019-05-17       Impact factor: 4.623

Review 5.  Patient-reported outcome measures in inflammatory bowel disease.

Authors:  Wael El-Matary
Journal:  Can J Gastroenterol Hepatol       Date:  2014-11

6.  Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study.

Authors:  Ignacio Marín-Jiménez; Pilar Nos; Eugeni Domènech; Sabino Riestra; Javier P Gisbert; Xavier Calvet; Xavier Cortés; Eva Iglesias; Jose M Huguet; Carlos Taxonera; Ramón Fernández; Daniel Carpio; Ana Gutiérrez; Jordi Guardiola; Luisa Castro Laria; Beatriz Sicilia; Luis Bujanda; Luis Cea-Calvo; Cristina Romero; Óscar Rincón; Berta Juliá; Julián Panés
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864

7.  Profiles of Patients Who Use Marijuana for Inflammatory Bowel Disease.

Authors:  Ann Marie Kerlin; Millie Long; Michael Kappelman; Christopher Martin; Robert S Sandler
Journal:  Dig Dis Sci       Date:  2018-03-29       Impact factor: 3.199

8.  Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis.

Authors:  P D R Higgins; M Schwartz; J Mapili; I Krokos; J Leung; E M Zimmermann
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

9.  Variation in Care of Inflammatory Bowel Diseases Patients in Crohn's and Colitis Foundation of America Partners: Role of Gastroenterologist Practice Setting in Disease Outcomes and Quality Process Measures.

Authors:  Kimberly N Weaver; Michael D Kappelman; Robert S Sandler; Christopher F Martin; Wenli Chen; Kristen Anton; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

10.  Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease.

Authors:  Matthew Geisz; Christina Ha; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Robert S Sandler; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.